Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 24 Sep 2026 · Editorial standards

Fulvestrant is named as a drug or biological intervention in 89 clinical trials in our USA, China, UK, India and Ireland trial registers, 49 of which are recruiting. Lead sponsors include Eli Lilly and Company (8), Hoffmann-La Roche (8) and Pfizer (7). Registered phases: Phase 3, Phase 1, Phase 2, Phase 1/2, Phase 2/3, Phase 4 and Observational. Conditions studied include Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer.

Clinical trials of Fulvestrant

89 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT05646862	A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy Breast Cancer	Phase 3	Recruiting	Hoffmann-La Roche	UK, USA, China
NCT05696626	Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ClinicalTrials.gov ↗) Metastatic Breast Cancer	Phase 3	Recruiting	LeonaBio	UK, USA, China
NCT06380751	Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (ClinicalTrials.gov ↗) Advanced Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
NCT06757634	Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) Breast Cancer	Phase 3	Recruiting	Celcuity Inc	USA, China
NCT06982521	Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer (ClinicalTrials.gov ↗) PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor	Phase 3	Recruiting	Relay Therapeutics, Inc.	UK, USA
NCT07024173	A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer (ClinicalTrials.gov ↗) Locally Advanced Breast Cancer, Metastatic Breast Cancer	Phase 3	Recruiting	Shandong Suncadia Medicine Co., Ltd.	China
NCT07062965	A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Recruiting	Pfizer	UK, USA, India, China
NCT07174336	A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Breast Neoplasms, Neoplasm Metastasis	Phase 3	Recruiting	Eli Lilly and Company	Ireland, UK, USA, China
NCT07207070	A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Recruiting	Risen (Suzhou) Pharma Tech Co., Ltd.	China
NCT07354022	A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (ClinicalTrials.gov ↗) Locally Advanced or Metastatic Breast Cancer	Phase 3	Recruiting	Shandong Suncadia Medicine Co., Ltd.	China
NCT04606446	Study of PF-07248144 in Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer	Phase 2	Recruiting	Pfizer	USA, China
NCT06145308	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (ClinicalTrials.gov ↗) Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
NCT06979596	A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (ClinicalTrials.gov ↗) Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
NCT07117630	An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	Fudan University	China
NCT07180160	Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer (ClinicalTrials.gov ↗) Advanced Breast Cancer	Phase 2	Recruiting	Wenjin Yin	China
NCT07330544	A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
NCT07368998	To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	Hoffmann-La Roche	UK, USA
NCT07405801	A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	Hoffmann-La Roche	UK, USA
NCT07498478	Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	TransThera Sciences (Nanjing), Inc.	China
NCT07666555	A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy. (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	Fudan University	China
NCT03424005	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (ClinicalTrials.gov ↗) Metastatic Breast Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA
NCT05573126	Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (ClinicalTrials.gov ↗) Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer	Phase 1/2	Recruiting	Ellipses Pharma	UK, USA
NCT05735080	Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (ClinicalTrials.gov ↗) Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor	Phase 1/2	Recruiting	Incyclix Bio	USA
NCT05768139	First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Breast Cancer, Solid Tumors, Adult	Phase 1/2	Recruiting	Eli Lilly and Company	Ireland, USA
NCT05867251	Study of AVZO-021 in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer	Phase 1/2	Recruiting	Avenzo Therapeutics, Inc.	USA
NCT06726148	Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer	Phase 1/2	Recruiting	Novartis Pharmaceuticals	UK, USA, China
NCT06736704	SNV4818 in Participants With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors	Phase 1/2	Recruiting	Pikavation Therapeutics, Inc.	USA
NCT06993844	Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors, Advanced Breast Cancer	Phase 1/2	Recruiting	Ensem Therapeutics	USA, China
NCT06998407	ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (ClinicalTrials.gov ↗) HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer	Phase 1/2	Recruiting	Avenzo Therapeutics, Inc.	USA
NCT07109726	A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations (ClinicalTrials.gov ↗) Breast Cancer, Endometrial Cancer, Ovarian Cancer	Phase 1/2	Recruiting	Terremoto Biosciences Inc.	USA
NCT07235176	Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients (ClinicalTrials.gov ↗) Advanced ER+/HER2- Breast Cancer	Phase 1/2	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
NCT07287917	Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (ClinicalTrials.gov ↗) Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer	Phase 1/2	Recruiting	Aminex Therapeutics, Inc.	USA
NCT07288359	Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer	Phase 1/2	Recruiting	Novartis Pharmaceuticals	USA
NCT07558733	Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer (ClinicalTrials.gov ↗) HR+ HER2- Breast Cancer	Phase 1/2	Recruiting	Faeth Therapeutics	USA
NCT05216432	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (ClinicalTrials.gov ↗) PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer	Phase 1	Recruiting	Relay Therapeutics, Inc.	USA
NCT05307705	A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (ClinicalTrials.gov ↗) Breast Cancer	Phase 1	Recruiting	Eli Lilly and Company	UK, USA, China
NCT06120283	BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer	Phase 1	Recruiting	BeOne Medicines	USA, China
NCT06515470	Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer Breast Cancer	Phase 1	Recruiting	Biotheryx, Inc.	USA
NCT06625775	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
NCT06756932	BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer	Phase 1	Recruiting	BeOne Medicines	USA, China
NCT06784193	Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Phase 1	Recruiting	Olema Pharmaceuticals, Inc.	USA
NCT06995482	Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers (ClinicalTrials.gov ↗) Healthy Postmenopausal Women	Phase 1	Recruiting	Kashiv BioSciences, LLC	USA, India
NCT06997029	A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer	Phase 1	Recruiting	Bristol-Myers Squibb	USA
NCT07029399	A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors (ClinicalTrials.gov ↗) HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors	Phase 1	Recruiting	NiKang Therapeutics, Inc.	USA
NCT07226349	A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor	Phase 1	Recruiting	BeOne Medicines	USA, China
NCT07318805	A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer	Phase 1	Recruiting	Pfizer	USA
NCT07540572	A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)	Phase 1	Recruiting	IDEAYA Biosciences	USA
NCT07604571	Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer (ClinicalTrials.gov ↗) Advanced HR+/HER2- Breast Cancer	Phase 1	Recruiting	Novartis Pharmaceuticals	USA
NCT07347600	A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (ClinicalTrials.gov ↗) Locally Advanced Breast Cancer, Metastatic Breast Cancer	Observational	Recruiting	Hoffmann-La Roche	China
NCT06929325	Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors (ClinicalTrials.gov ↗) HR+/HER2- Advanced/Metastatic Breast Cancer	Phase 3	Not yet open	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	China
NCT07235618	A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer (ClinicalTrials.gov ↗) Locally Advanced or Metastatic Breast Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
NCT07811232	A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers (ClinicalTrials.gov ↗) Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms	Phase 1/2	Not yet open	Advenchen Pharmaceuticals, LLC.	USA
NCT07163481	A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors (ClinicalTrials.gov ↗) Stage IV (Metastatic) Breast Cancer	Phase 1	Not yet open	Hunan Cancer Hospital	China
NCT07787520	A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors (ClinicalTrials.gov ↗) Patients With Advanced Solid Tumors	Phase 1	Not yet open	Laekna Limited	China
NCT05161195	Roll-over Study to Allow Continued Access to Ribociclib (ClinicalTrials.gov ↗) Metastatic Breast Cancer	Phase 4	Active, closed	Novartis Pharmaceuticals	USA, India, China
NCT00099437	Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Active, closed	AstraZeneca	USA, India
NCT02107703	A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (ClinicalTrials.gov ↗) Breast Neoplasms	Phase 3	Active, closed	Eli Lilly and Company	USA, China
NCT02763566	A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Active, closed	Eli Lilly and Company	India, China
NCT04305496	Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (ClinicalTrials.gov ↗) Locally Advanced (Inoperable) or Metastatic Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China
NCT04862663	Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (ClinicalTrials.gov ↗) Locally Advanced (Inoperable) or Metastatic Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
NCT04975308	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Breast Neoplasms, Neoplasm Metastasis	Phase 3	Active, closed	Eli Lilly and Company	USA, India, China
NCT05038735	Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Active, closed	Novartis Pharmaceuticals	Ireland
NCT05169567	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (ClinicalTrials.gov ↗) Breast Neoplasm, Neoplasm Metastasis	Phase 3	Active, closed	Eli Lilly and Company	USA
NCT05306340	A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) (ClinicalTrials.gov ↗) Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Genentech, Inc.	UK, USA
NCT05365178	To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (ClinicalTrials.gov ↗) HR-positive, HER2-negative Breast Neoplasms	Phase 3	Active, closed	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	China
NCT05501886	Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Active, closed	Celcuity Inc	UK, USA, India, China
NCT05654623	A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer Advanced Breast Cancer	Phase 3	Active, closed	Pfizer	UK, USA, India, China
NCT06016738	OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer	Phase 3	Active, closed	Olema Pharmaceuticals, Inc.	UK, USA
NCT06065748	A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) (ClinicalTrials.gov ↗) Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA, India, China
NCT06635447	Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (ClinicalTrials.gov ↗) Breast Cancer	Phase 3	Active, closed	AstraZeneca	China
NCT06680921	A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Jiangsu Simcere Pharmaceutical Co., Ltd.	China
NCT04191499	A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Breast Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	UK, USA, China
NCT04214288	A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer Advanced ER-Positive HER2-Negative Breast Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA
NCT04553133	PF-07104091 as a Single Agent and in Combination Therapy Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer	Phase 2	Active, closed	Pfizer	USA, China
NCT04567420	DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Active, closed	Criterium, Inc.	USA
NCT04576455	A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) (ClinicalTrials.gov ↗) Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, China
NCT04579380	Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (ClinicalTrials.gov ↗) Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
NCT05226871	Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies Breast Cancer, Head and Neck Cancer	Phase 2	Active, closed	Pfizer	USA, China
NCT06105632	A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment Advanced or Metastatic Breast Cancer	Phase 2	Active, closed	Pfizer	UK, USA, India, China
NCT06428396	Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (ClinicalTrials.gov ↗) Metastatic Breast Cancer	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
NCT06957379	Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy (ClinicalTrials.gov ↗) HR+/HER2- Advanced/Metastatic Breast Cancer	Phase 2	Active, closed	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	China
NCT05251714	CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer Advanced Solid Tumor, Breast Cancer	Phase 1/2	Active, closed	Treadwell Therapeutics, Inc	USA
NCT02057133	A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (ClinicalTrials.gov ↗) Breast Neoplasms	Phase 1	Active, closed	Eli Lilly and Company	USA
NCT03006172	To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer Breast Cancer, Solid Tumor	Phase 1	Active, closed	Genentech, Inc.	UK, USA
NCT05238922	Study of INCB123667 in Subjects With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumors	Phase 1	Active, closed	Incyte Corporation	UK, USA
NCT05870579	[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer	Phase 1	Active, closed	Novartis Pharmaceuticals	USA, China
NCT06239467	First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (ClinicalTrials.gov ↗) Advanced Cancer, Breast Cancer, Advanced Solid Tumors	Phase 1	Active, closed	OnKure, Inc.	USA
NCT06257264	A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors (ClinicalTrials.gov ↗) Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer	Phase 1	Active, closed	BeiGene	USA, China
NCT07557004	A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. (ClinicalTrials.gov ↗) HR+ / HER2- Advanced Breast Cancer	Phase 1	Active, closed	Nanjing Sanhome Pharmaceutical, Co., Ltd.	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

82 conditions

Condition (as registered)	Trials
Breast Cancer	32
Metastatic Breast Cancer	12
Advanced Breast Cancer	9
Breast Neoplasms	5
Advanced Solid Tumor	5
Neoplasm Metastasis	3
Advanced HR+/HER2- Breast Cancer	3
Ovarian Cancer	3
Advanced Solid Tumors	3
Locally Advanced or Metastatic Breast Cancer	3
PIK3CA Mutation	2
Hormone Receptor Positive Tumor	2
Locally Advanced (Inoperable) or Metastatic Breast Cancer	2
Advanced CCNE1-amplified Solid Tumors	2
Hormone-receptor-positive Breast Cancer	2
HER2-negative Breast Cancer	2
Small Cell Lung Cancer	2
Solid Tumor, Adult	2
HR+/HER2- Breast Cancer	2
HR+, HER2-, Advanced Breast Cancer	2
HR+ HER2- Breast Cancer	2
HR+/HER2- Advanced/Metastatic Breast Cancer	2
Locally Advanced Breast Cancer	2
Solid Tumors, Adult	1
Advanced or Metastatic Breast Cancer	1
Solid Tumor	1
Advanced ER-Positive HER2-Negative Breast Cancer	1
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer	1
HER2- Negative Breast Cancer	1
Solid Tumors	1
Extensive-stage Small Cell Lung Cancer	1
Malignant Neoplasm	1
ER Positive Breast Cancer	1
Hormone Receptor-positive Breast Cancer	1
Hormone Receptor Positive HER-2 Negative Breast Cancer	1
Uterine Neoplasms	1
Uterine Cervical Neoplasms	1
Biliary Tract Neoplasms	1
Urologic Neoplasms	1
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer	1

+ 42 more conditions in the trial records above.

Trials by country register

Register	Fulvestrant trials
Clinical trials in USA	67
Clinical trials in China	49
Clinical trials in UK	27
Clinical trials in India	12
Clinical trials in Ireland	3

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fulvestrant works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fulvestrant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Fulvestrant

Clinical trials of Fulvestrant

Conditions studied

Sponsors

Trials by country register

How this page is built